These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 30653256)

  • 1. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
    Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
    Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
    Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
    Volckmar AL; Christopoulos P; Kirchner M; Allgäuer M; Neumann O; Budczies J; Rempel E; Horak P; Glade J; Goldschmid H; Seker-Cin H; Brandt R; Kriegsmann M; Leichsenring J; Winter H; Faehling M; Fischer JR; Heußel CP; Herth F; Brummer T; Fröhling S; Schirmacher P; Thomas M; Endris V; Penzel R; Kazdal D; Bochtler T; Stenzinger A
    Lung Cancer; 2021 Apr; 154():131-141. PubMed ID: 33667718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
    Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.
    Lindquist KE; Karlsson A; Levéen P; Brunnström H; Reuterswärd C; Holm K; Jönsson M; Annersten K; Rosengren F; Jirström K; Kosieradzki J; Ek L; Borg Å; Planck M; Jönsson G; Staaf J
    Oncotarget; 2017 May; 8(21):34796-34810. PubMed ID: 28415793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor molecular profiling of NSCLC patients using next generation sequencing.
    Tsoulos N; Papadopoulou E; Metaxa-Mariatou V; Tsaousis G; Efstathiadou C; Tounta G; Scapeti A; Bourkoula E; Zarogoulidis P; Pentheroudakis G; Kakolyris S; Boukovinas I; Papakotoulas P; Athanasiadis E; Floros T; Koumarianou A; Barbounis V; Dinischiotu A; Nasioulas G
    Oncol Rep; 2017 Dec; 38(6):3419-3429. PubMed ID: 29130105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
    Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
    Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer.
    Nindra U; Pal A; Bray V; Yip PY; Tognela A; Roberts TL; Becker TM; Williamson J; Farzin M; Li JJ; Lea V; Hagelamin A; Ng W; Wang B; Lee CS; Chua W
    Intern Med J; 2024 Apr; 54(4):596-601. PubMed ID: 37713593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
    Cohen D; Hondelink LM; Solleveld-Westerink N; Uljee SM; Ruano D; Cleton-Jansen AM; von der Thüsen JH; Ramai SRS; Postmus PE; Graadt van Roggen JF; Hoppe BPC; Clahsen PC; Maas KW; Ahsmann EJM; Ten Heuvel A; Smedts F; van Rossem RN; van Wezel T
    J Thorac Oncol; 2020 Jun; 15(6):1000-1014. PubMed ID: 32014610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.